Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80...
Clinical Trial
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and...
Cryoport Reports Third Quarter 2024 Financial Results
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of...
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Avinger Reports Third Quarter 2024 Results
Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 /...
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe...
Cellev8 Nutrition Shareholder Update
WELLINGTON, FL / ACCESSWIRE / November 7, 2024 / Dear Valued Shareholders,I am thrilled to share with you some of...
Health Union Releases 2024 Findings of “In America” and “Patient Experience” Syndicated Healthcare Research, Offering Unmatched Patient Insights
With data from over 37,000 individuals across 50+ conditions, Health Union's 2024 syndicated healthcare research findings provide fresh perspectives on...
Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device
New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif., Nov. 7, 2024 /PRNewswire/ --...
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company...
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by...
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid...
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discoveryROCHESTER, N.Y., Nov. 07, 2024...
KORU Medical Systems to Participate in Upcoming Investor Conferences
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
Ainos Reports Third Quarter 2024 Financial Results
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / November...
Flatiron Health Announces Research to be Presented at International Society for Pharmacoeconomics and Outcomes Research Europe 2024 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced their planned presence at the International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR...